Imaging agents analogous to these antagonists have also been developed, as sensitive depiction of CXCR4 could be used to effectively stratify patients [23] and monitor therapeutic outcome with emphasis on SPECT imaging [24–26], optical imaging [27–32] and PET [33–44]; PET-dedicated radiotracers have seen the most success, with [68Ga]Pentixafor, a peptide-based CXCR4-targeting molecule, currently in multiple clinical trials including patients with neuroendocrine tumors (ClinicalTrials. This evidence concerns the gene CXCR4 and neuroendocrine neoplasm.